{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:43:38Z","timestamp":1792284218825,"version":"4.4.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T00:00:00Z","timestamp":1363824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0059941","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T20:58:16Z","timestamp":1363899496000},"page":"e59941","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":103,"title":["Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients"],"prefix":"10.1371","volume":"8","author":[{"given":"Fabio P.","family":"Nunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"di Tomaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,21]]},"reference":[{"key":"ref1","unstructured":"CBTRUS (2012 March) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004\u221222008."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/0973-1482.80462","article-title":"Fractionated stereotactic radiosurgery for the treatment of meningiomas","volume":"7","author":"C Bria","year":"2011","journal-title":"J Cancer Res Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11910-009-0034-5","article-title":"Advances in meningioma therapy","volume":"9","author":"AD Norden","year":"2009","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmg.2010.085241","article-title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset","volume":"48","author":"MJ Smith","year":"2011","journal-title":"J Med Genet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/342716","article-title":"Predictors of the risk of mortality in neurofibromatosis 2","volume":"71","author":"ME Baser","year":"2002","journal-title":"Am J Hum Genet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/08830738030180101301","article-title":"Neurofibromatosis 2 in the pediatric population","volume":"18","author":"F Nunes","year":"2003","journal-title":"J Child Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/107327480200902S05","article-title":"Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers","volume":"9","author":"LS Rosen","year":"2002","journal-title":"Cancer Control"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"N Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"SR Plotkin","year":"2009","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr012","article-title":"Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab","volume":"22","author":"S Goutagny","year":"2011","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/annonc\/mdq634","article-title":"Bevacizumab-induced regression of anaplastic meningioma","volume":"21","author":"MJ Puchner","year":"2010","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"E Lou","year":"2012","journal-title":"J Neurooncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"L Nayak","year":"2012","journal-title":"J Neurooncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"JW Goodwin","year":"1993","journal-title":"J Neurooncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","article-title":"Salvage chemotherapy with CPT-11 for recurrent meningioma","volume":"78","author":"MC Chamberlain","year":"2006","journal-title":"J Neurooncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"MC Chamberlain","year":"2004","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"DR Johnson","year":"2011","journal-title":"Neuro Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/2011.1.FOCUS111","article-title":"Treatment of unresectable skull base meningiomas with somatostatin analogs","volume":"30","author":"C Schulz","year":"2011","journal-title":"Neurosurg Focus"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/07357900601062339","article-title":"Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma","volume":"24","author":"SM Grunberg","year":"2006","journal-title":"Cancer Invest"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, <etal>et al<\/etal>.. (2009) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol.","DOI":"10.1007\/s11060-009-9948-7"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01\u221208)","volume":"11","author":"PY Wen","year":"2009","journal-title":"Neuro Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"MC Chamberlain","year":"2008","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","article-title":"The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B","volume":"40","author":"SE Kaba","year":"1997","journal-title":"Neurosurgery"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3171\/jns.1997.86.5.0840","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea","volume":"86","author":"UM Schrell","year":"1997","journal-title":"J Neurosurg"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","article-title":"Non-resectable slow-growing meningiomas treated by hydroxyurea","volume":"67","author":"D Loven","year":"2004","journal-title":"J Neurooncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3171\/jns.2002.97.2.0341","article-title":"Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma","volume":"97","author":"WP Mason","year":"2002","journal-title":"J Neurosurg"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"SR Plotkin","year":"2012","journal-title":"Otol Neurotol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0059941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T09:20:25Z","timestamp":1589016025000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0059941"}},"subtitle":[],"editor":[{"given":"Russell","family":"O. Pieper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,21]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0059941","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,21]]}}}